Nanomedicine has progressed far beyond its early role as an experimental drug-carrier toolbox and today stands as a clinically validated enabling technology. Liposomal formulations and albumin-bound nanoparticles have transformed cancer therapy, while lipid nanoparticle (LNP) platforms accelerated the rapid development...
A. Grattoni, Marco M. Paci, Noah Arnold et al.· Biomedical microdevices· 0 citations
Messenger RNA (mRNA) cancer vaccines have progressed rapidly, with personalized platforms such as mRNA-4157 and BNT122 demonstrating feasibility, safety, and durable immune activity but limited scalability. Off-the-shelf constructs, including BNT111 and BNT113, enable faster, broader deployment, yet they risk reduced p...
Seongdong Jeong, Benjamin R. Schrank, James J. Mancuso et al.· Cancer Discovery· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.